{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:23:12Z","timestamp":1781756592526,"version":"3.54.5"},"reference-count":22,"publisher":"Norwegian Medical Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.17.0493","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T05:57:46Z","timestamp":1519106266000},"source":"Crossref","is-referenced-by-count":1,"title":["Guidelines for treatment of sepsis"],"prefix":"10.4045","volume":"138","author":[{"given":"Erik Refsland","family":"Kaspersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"R\u00e6der","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vegard","family":"Dahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"key":"ref=1","unstructured":"Nyg\u00e5rd\u00a0ST, Langeland\u00a0N, Flaatten\u00a0HK et al. Aetiology, antimicrobial therapy and outcome of patients with community acquired severe sepsis: a prospective study in a Norwegian university hospital. BMC Infect Dis 2014; 14: 121. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24588984&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2F1471-2334-14-121"},{"key":"ref=2","unstructured":"Singer\u00a0M, Deutschman\u00a0CS, Seymour\u00a0CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801\u201310. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26903338&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjama.2016.0287"},{"key":"ref=3","unstructured":"Tidlig oppdagelse av sepsis: Pasientsikkerhetsprogrammet I trygge hender.http:\/\/www.pasientsikkerhetsprogrammet.no\/om-oss\/innsatsomr%C3%A5der\/tidlig-oppdagelse-og-behandling-av-sepsis (24.9.2017)."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Seymour\u00a0CW, Gesten\u00a0F, Prescott\u00a0HC et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N Engl J Med 2017; 376: 2235\u201344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28528569&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1703058","DOI":"10.1056\/NEJMoa1703058"},{"key":"ref=5","unstructured":"Rhodes\u00a0A, Evans\u00a0LE, Alhazzani\u00a0W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45: 486\u2013552. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28098591&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FCCM.0000000000002255"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Norsk legemiddelh\u00e5ndbok. T1.10 Sepsis. http:\/\/legemiddelhandboka.no\/Terapi\/s%C3%B8ker\/+%2Bsepsis\/1780(18.3.2017).","DOI":"10.1109\/TITS.2017.2757200"},{"key":"ref=7","unstructured":"Helsedirektoratet. Nasjonal faglig retningslinje for bruk av antibiotika i sykehus. Sepsis. https:\/\/helsedirektoratet.no\/retningslinjer\/antibiotika-i-sykehus\/seksjon?Tittel=sepsis-1116 (18.3.2017)."},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"De Groot\u00a0B, Struyk\u00a0B, Najafi\u00a0R et al. Inclusion of emergency department patients in early stages of sepsis in a quality improvement programme has the potential to improve survival: a prospective dual-centre study. Emerg Med J 2017; 34: 578\u201385. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28515132&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Femermed-2015-205645","DOI":"10.1136\/emermed-2015-205645"},{"key":"ref=9","unstructured":"Regjeringen. Oversikt over landets helseforetak. http:\/\/www.regjeringen.no\/no\/tema\/helse-og-omsorg\/sykehus\/innsikt\/oversikt-over-landets-helseforetak\/id485362(18.3.2017)."},{"key":"ref=10","unstructured":"Nasjonal helse- og sykehusplan. https:\/\/www.regjeringen.no\/no\/tema\/helse-og-omsorg\/sykehus\/nasjonal-helse--og-sykehusplan2\/id2461509\/(15.12.2017)."},{"key":"ref=11","unstructured":"Norsk legemiddelh\u00e5ndbok. T1 Infeksjonssykdommer. Tabell 8 Aktuelle biokjemiske mark\u00f8rer for inflammasjon og organdysfunksjon ved sepsis.http:\/\/legemiddelhandboka.no\/Terapi\/3203 (24.9.2017)."},{"key":"ref=12","unstructured":"Norsk legemiddelh\u00e5ndbok. T1 Infeksjonssykdommer. Tabell 9 Aktuelle mikrobiologiske pr\u00f8ver ved sepsis.http:\/\/legemiddelhandboka.no\/Terapi\/3240 (24.9.2017)."},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Nord\u00f8y\u00a0I, Laake\u00a0JH. Uforsvarlige retningslinjer for antibiotikabruk i\u00a0sykehus. Tidsskr Nor Legeforen 2013; 133: 1056. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23712164&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.13.0376","DOI":"10.4045\/tidsskr.13.0376"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Paul\u00a0M, Silbiger\u00a0I, Grozinsky\u00a0S et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 1: CD003344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16437452&dopt=Abstract","DOI":"10.1002\/14651858.CD003344.pub2"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Paul\u00a0M, Lador\u00a0A, Grozinsky-Glasberg\u00a0S et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014; 1: CD003344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24395715&dopt=Abstract","DOI":"10.1002\/14651858.CD003344.pub3"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Haug\u00a0JB, Berild\u00a0D, Blomberg\u00a0B et al. Aminoglykosider ved alvorlig sepsis. Tidsskr Nor Legeforen 2013; 133: 1553\u20134. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23970249&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.13.0866","DOI":"10.4045\/tidsskr.13.0866"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Skrede\u00a0S, Nyg\u00e5rd\u00a0ST, Langeland\u00a0N et al. Aminoglykosider kan redusere risiko. Tidsskr Nor Legeforen 2013; 133: 1554. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23970250&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.13.0868","DOI":"10.4045\/tidsskr.13.0868"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Marik\u00a0PE, Linde-Zwirble\u00a0WT, Bittner\u00a0EA et al. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database. Intensive Care Med 2017; 43: 625\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28130687&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00134-016-4675-y","DOI":"10.1007\/s00134-016-4675-y"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Marik\u00a0P, Bellomo\u00a0R. A rational approach to fluid therapy in sepsis. Br J Anaesth 2016; 116: 339\u201349. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26507493&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fbja%2Faev349","DOI":"10.1093\/bja\/aev349"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Cecconi\u00a0M, De Backer\u00a0D, Antonelli\u00a0M et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014; 40: 1795\u2013815. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25392034&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00134-014-3525-z","DOI":"10.1007\/s00134-014-3525-z"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Mutter\u00a0TC, Ruth\u00a0CA, Dart\u00a0AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2013; 7: CD007594. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23881659&dopt=Abstract","DOI":"10.1002\/14651858.CD007594.pub3"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"De Backer\u00a0D, Aldecoa\u00a0C, Njimi\u00a0H et al. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 2012; 40: 725\u201330. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22036860&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FCCM.0b013e31823778ee","DOI":"10.1097\/CCM.0b013e31823778ee"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Retningslinjer for behandling av sepsis"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:10:42Z","timestamp":1781701842000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2018\/02\/originalartikkel\/retningslinjer-behandling-av-sepsis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,19]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,2,20]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.17.0493","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,19]]}}}